GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0

作者：

Phillips, Tycel ^{[1
]}

Matasar, Matthew ^{[2
]}

Eyre, Toby A. ^{[3
]}

Gine, Eva ^{[4
]}

de L'Etang, Audrey Filezac ^{[5
]}

Byrne, Ben ^{[6
]}

Lundberg, Linda ^{[5
]}

Padovani, Alejandra ^{[5
]}

Boetsch, Christophe ^{[5
]}

Bottos, Alessia ^{[5
]}

Qayum, Naseer ^{[6
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[3] Oxford Univ Hosp NHS Trust, Oxford, England

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] F Hoffmann La Roche Ltd, Basel, Switzerland

[6] Roche Prod Ltd, Welwyn Garden City, Herts, England

来源：

关键词：

MCL; clinical trials; non-Hodgkin lymphoma; bispecific antibody therapy; adverse events; mantle cell lymphoma; phase; 3;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MCL-339

引用

页码：S515 / S515

页数：1